The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL

Chronic myeloid leukemia (CML) is characterized by constitutively active fusion protein tyrosine kinase BCR-ABL. Although the tyrosine kinase inhibitor (TKI) against BCR-ABL, imatinib, is the first-line therapy for CML, acquired resistance almost inevitably emerges. The underlying mechanism are poin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ru, Yi, Wang, Qinhao, Liu, Xiping, Zhang, Mei, Zhong, Daixing, Ye, Mingxiang, Li, Yuanchun, Han, Hua, Yao, Libo, Li, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916441/
https://www.ncbi.nlm.nih.gov/pubmed/27329306
http://dx.doi.org/10.1038/srep28352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916441/
https://www.ncbi.nlm.nih.gov/pubmed/27329306
http://dx.doi.org/10.1038/srep28352

Ejemplares similares